CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: November 5, 2019
Result type: Reports
Project Number: SE0532-000
Product Line: Reimbursement Review

Generic Name: infliximab

Brand Name: Renflexis

Manufacturer: Merck Canada Inc.

Indications: rheumatoid arthritis, ankylosing spondylitis, adult Crohn’s disease, pediatric Crohn’s disease, fistulising Crohn’s disease, adult ulcerative colitis, pediatric ulcerative colitis, psoriatic arthritis, plaque psoriasis

Submission Type: Initial

Project Status: Complete

Biosimilar: Yes

Date Recommendation Issued: February 20, 2018

Recommendation Type: Reimburse with clinical criteria and/or conditions

Fee Schedule: Schedule C

Key Milestones2

Call for patient input postedAugust 04, 2017
Patient group input closedSeptember 26, 2017

- Patient input submission received

Patient input summary sent for review to patient input groupsOctober 05, 2017
Patient group comments on input summary closedOctober 13, 2017

- Patient input summary feedback received

Submission receivedSeptember 05, 2017
Submission accepted for reviewSeptember 19, 2017
Review initiatedSeptember 20, 2017
Draft CADTH review report(s) sent to sponsorNovember 28, 2017
Comments from sponsor on draft CADTH review report(s) receivedDecember 07, 2017
Redaction requests from sponsor on draft CADTH review report(s) receivedDecember 14, 2017
CADTH review team's comments on draft CADTH review report(s) sent to sponsorJanuary 05, 2018
Canadian Drug Expert Committee (CDEC) meetingJanuary 17, 2018
CDEC recommendation & redacted CADTH review report(s) sent to sponsor and drug plansJanuary 29, 2018
Embargo period ended and validation of redacted CADTH review report(s) receivedFebruary 12, 2018
CDEC Final Recommendation issued to sponsor and drug plansFebruary 20, 2018
CDEC Final Recommendation postedFebruary 22, 2018
Final CADTH review report(s) and patient input postedApril 24, 2018